Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc.SLS · Entity 4313 | Director | March 14, 2019 | March 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SELLAS Life Sciences Group, Inc.
Report date March 14, 2019 · Filed March 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.38 · Expires 2029-03-14 | Direct | 25,000 |
Reported balance
After 2019-03-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-14 · Grant · Acquired 25,000 · Balance 25,000 F1: The shares subject to the option will fully vest on the earlier of (x) March 14, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will fully vest on the earlier of (x) March 14, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2019 Filed Mar 18, 2019 23:03 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000899243-19-008202 · doc4.xml · derivative · entry 1 Ghiglieri Stephen F · CIK 0001394548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-03-14 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) March 14, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 22:31 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $5.23 | $0.00 |
DisclosureSEC source: 0001209191-18-037552 · doc4.xml · derivative · entry 1 Ghiglieri Stephen F · CIK 0001394548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2028-06-11 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) June 12, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 23:59 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.24 | $0.00 |
DisclosureSEC source: 0001209191-18-020016 · doc4.xml · derivative · entry 1 Ghiglieri Stephen F · CIK 0001394548 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: The option shares will vest and became exercisable in equal monthly installments for thirty-six (36) months following the March 13, 2018 grant date, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| November 01, 2016 Filed Nov 15, 2016 23:26 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantStock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $0.19 | $0.00 |
DisclosureSEC source: 0001394548-16-000003 · primary_doc.xml · derivative · entry 1 Ghiglieri Stephen F · CIK 0001394548 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2026-11-01 F1 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F2 · shares: The Reporting Person obtained the securities pursuant to a new hire Employment Agreement dated November 1, 2016. The securities were convertible into common stock at the rate of 1 share of common stock for each 1 stock option share, or an aggregate 1,000,000 shares of common stock (pre-reverse stock split). The securities were converted into 50,000 stock options at a price of $3.80 (post-reverse stock split) as of November 14, 2016. F3 · derivative.exercise_date: This stock option vests in equal, quarterly installments over four years, beginning three months after November 1, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.